In vitro inhibition of androstenedione reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia

Journal of Steroid Biochemistry and Molecular Biology

Volumn 67, Issue 1, 1998, Pages 49-55

  Weisser, H ^a   Krieg, M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; FINASTERIDE;

ANDROGEN METABOLISM; ARTICLE; BINDING AFFINITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PROSTATE HYPERTROPHY; RECEPTOR AFFINITY; STROMA CELL;

AGED; AGED, 80 AND OVER; CHOLESTENONE 5 ALPHA-REDUCTASE; EPITHELIAL CELLS; FINASTERIDE; HUMANS; KINETICS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; STROMAL CELLS;

EID: 0031787210     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00071-5     Document Type: Article

References (23)

1. Krieg, M. and Tunn, S., Androgens and human benign prostatic hyperplasia (BPH). In Testosterone. Action, Deficiency, Substitution, eds. E. Nieschlag and H. M. Behre. Springer Verlag, Berlin/Heidelberg/New York/London/Paris/Tokyo/ Hong Kong/Barcelona, 1990, pp. 219-244.
2. Krieg M., Weisser H. and Tunn S., Potential activities of androgen metabolizing enzymes in human prostate. J. Steroid Biochem. Molec. Biol 53 (1995) 395-400.
3. Tunn S., Hochstrate H., Grunwald I., Flüchter St. H. and Krieg M., Effect of aging on kinetic parameters of 5α-reductase in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab. 67 (1988) 979-985.
4. Weisser H. and Krieg M., Kinetic analysis of androstenedione 5α-reductase in epithelium and stroma of human prostate. Steroids 62 (1997) 589-594.
5. ®) in epithelium and stroma of human benign prostatic hyperplasia. Steroids 59 (1994) 616-620.
6. Tunn S., Claus S., Schulze H., Braun B.-E. and Krieg M., 5α-androstane-3β,17β-diol hydroxylating enzymes in stroma and epithelium of human benign prostatic hyperplasia (BPH). J. Steroid Biochem. 28 (1987) 257-265.
7. Tunn S., Haumann R., Hey J., Flüchter St. H. and Krieg M., Effect of aging on kinetic parameters of 3α(β)-hydroxysteroid oxidoreductases in epithelium and stroma of human normal and hyperplastic prostate. J. Clin. Endocrinol. Metab. 71 (1990) 732-739.
8. Tunn S., Schulze H. and Krieg M., 17β-hydroxysteroid oxido-reductase in epithelium and stroma of human prostate. J. Steroid Biochem. 46 (1993) 91-101.
9. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J., Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275.
10. Walter, K. and Schutt, C., Saure und alkalische Phosphatase im Serum (Zwei-Punkt- Methode). In Methoden der enzymatischen Analysen, ed. H. U. Bergmeier. Verlag Chemie, Weinheim, 1970, pp. 818-822.
11. Lineweaver H. and Burk D., The determination of enzyme dissociation constants. J. Am. Chem. Soc. 56 (1934) 658-666.
12. Dixon M., The determination of enzyme inhibitor constants. Biochem. J. 55 (1953) 170-171.
13. Gormley G. J., Stoner E., Rittmaster R. S., Gregg H. and Thompson D. L. et al., Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J. Clin. Endocrinol. Metab. 70 (1990) 1136-1141.
14. Habib F. K., Ross M., Tate R. and Chisholm G. D., Differential effect of finasteride on the tissue androgen concentration in benign prostatic hyperplasia. Clin. Endocrinol. 46 (1997) 137-144.
15. Rittmaster R. S., Normann R. W., Thomas L. N. and Rowden G., Evidence for atrophy and apoptosis in the prostate of men given finasteride. J. Clin. Endocrinol. Metab. 81 (1996) 814-819.
16. Russell D. W. and Wilson J. D., Steroid 5α-reductase: two genes/two enzymes. Ann. Rev. Biochem. 63 (1994) 25-61.
17. Silver R. I., Wiley E. L., Thigpen A. E., Guileyardo J. M., McConnell J. D. and Russell D. W., Cell type specific expression of steroid 5α-reductase 2. J. Urol. 152 (1994) 438-442.
18. Bonnet P., Reiter E., Bruyninx M., Sente B., Dombrowicz D., de Leval J., Closset J. and Heenen G., Benign prostatic hyperplasia and normal prostate ageing: differences in types I and II 5α-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. J. Clin. Endocrinol. Metab. 77 (1993) 1203-1208.
19. Bruchovsky N., Sadar M. D., Akakura K., Goldenberg S. L., Matsuoka K. and Rennie P. S., Characterization of 5α-reductase gene expression in stroma and epithelium of human prostate. J. Steroid Biochem. Mol. Biol. 59 (1996) 397-404.
20. Mellin T. N., Busch R. D. and Rasmusson G. H., Azasteroids as inhibitors of testosterone 5α-reductase in mammalian. J. Steroid Biochem. Mol. Biol. 44 (1993) 121-131.
21. Weisser H. and Krieg M., Lipid composition in epithelium and stroma of human benign prostatic hyperplasia. Prostate 30 (1997) 41-46.
22. Martini L., Zoppi S. and Motta M., Studies on the possible existence of two 5α-reductases in the rat prostate. J. Steroid Biochem. 24 (1986) 177-182.
23. Thigpen A. E., Cala K. M. and Russell D. W., Characterization of chinese hamster ovary cell lines expressing human steroid 5α-reductase isozymes. J. Biol. Chem. 268 (1993) 17404-17412.